On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ...

Pfizer, Inc. (PFE) stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance.

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

In search of a better approach to designing and developing these small proteins, researchers turned to ProtGPT2.

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season.

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

The FDA cautions the outcomes described in the complaints may have no connection to the drugs or could be unexpected side effects.

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

Royalty Pharma Plc (NASDAQ: RPRX) is one of the top most undervalued biotech stocks to buy now. In a report released on ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.